Drug Profile
Soblidotin
Alternative Names: TZT-1027; YHI-501Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator ASKA Pharmaceutical
- Developer Yakult Honsha
- Class Antineoplastics; Auristatins
- Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin modulators; Tubulin polymerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for phase-I development in Solid-tumours in Japan (IV, Infusion)
- 22 Mar 2007 Soblidotin licensed to Yakult Honsha worldwide
- 13 Oct 2005 Grelan Pharmaceutical has merged with Teikoku Hormone to form ASKA Pharmaceutical